lerapolturev
AXP000124.1 · Oncolytic virus
- Platform
- poliovirus (Sabin type 1 with HRV2 IRES)
- Originator
- Duke University (Matthias Gromeier)
- Sponsor
- Istari Oncology
Names
Virus
- Role
- Oncolytic
- Family
- Picornaviridae
- Virus
- poliovirus 1 (NCBI Taxonomy 12080)
- Strain
- Sabin type 1 with HRV2 IRES
- Replication
- replicating
- Modifications
- cognate IRES replaced by the human rhinovirus 2 IRES (PVSRIPO chimera)
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C184921
- FDA UNII
- MQ5GV2WUK4
Approvals
No regulatory approval recorded.
Clinical trials (12)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06177964 | Lerapolturev (PVSRIPO) in GBM | Recruiting | Phase 2 | 2024-07-15 | 2029-02 | 92 | Recurrent Supratentorial Glioblastoma |
| NCT04690699 | LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors | Terminated | Phase 1/2 | 2021-08-01 | 2024-04-04 | 4 | Bladder Cancer; Non-muscle-invasive Bladder Cancer; Solid Tumor |
| NCT04577807 | LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma | Completed | Phase 2 | 2020-11-17 | 2024-11-15 | 27 | Melanoma |
| NCT04479241 | LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma | Completed | Phase 2 | 2020-10-21 | 2024-06-05 | 25 | Brain Tumor; Glioblastoma; Recurrent Glioblastoma; Supratentorial Glioblastoma |
| NCT04125719 | PVSRIPO in Combination With Nivolumab in Melanoma | Withdrawn | Phase 1 | 2020-06-01 | 2024-10-01 | 0 | Melanoma |
| NCT03973879 | Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma | Withdrawn | Phase 1/2 | 2020-02 | 2024-01 | 0 | Malignant Glioma |
| NCT03564782 | Examining Bioactivity of PVSRIPO in Invasive Breast Cancer | Completed | Early phase 1 | 2019-06-30 | 2022-04-11 | 5 | Invasive Breast Cancer |
| NCT03712358 | PVSRIPO for Patients With Unresectable Melanoma | Terminated | Phase 1 | 2018-11-26 | 2021-03-23 | 12 | Melanoma |
| NCT03043391 | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | Completed | Phase 1 | 2017-11-07 | 2022-03-23 | 8 | Anaplastic Astrocytoma; Anaplastic Oligoastrocytoma; Anaplastic Oligodendroglioma; Atypical Teratoid/Rhabdoid Tumor of Brain; Embryonal Tumor of Brain; Ependymoma; Glioblastoma; Gliosarcoma; Malignant Glioma; Medulloblastoma; Pleomorphic Xanthoastrocytoma of Brain |
| NCT02986178 | Lerapolturev in Recurrent Malignant Glioma | Completed | Phase 2 | 2017-06-01 | 2022-09-30 | 121 | Malignant Glioma |
| NCT01491893 | PVSRIPO for Recurrent Glioblastoma (GBM) | Completed | Phase 1 | 2012-04-25 | 2017-06-27 | 61 | GBM; Glioblastoma; Glioma; Malignant Glioma |
| NCT04599647 | EAP for the Treatment of Glioblastoma With PVSRIPO | No longer available | Glioblastoma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 38215438 | The safety and accuracy of intratumoral catheter placement to infuse viral immunotherapies in children with malignant brain tumors: a multi-institutional study. | Journal of neurosurgery. Pediatrics | 2024 | cited by trial NCT03043391 |
| PMID 37004712 | Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial. | The Lancet. Child & adolescent health | 2023 | cited by trial NCT03043391 |
| PMID 37072349 | Intratumor childhood vaccine-specific CD4+ T-cell recall coordinates antitumor CD8+ T cells and eosinophils. | Journal for immunotherapy of cancer | 2023 | cited by trial NCT01491893 |
| PMID 36175036 | Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma. | Journal for immunotherapy of cancer | 2022 | cited by trial NCT03712358 |
| PMID 33875611 | Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma. | Journal for immunotherapy of cancer | 2021 | cited by trial NCT03712358 |
| PMID 29943666 | Recurrent Glioblastoma Treated with Recombinant Poliovirus. | The New England journal of medicine | 2018 | cited by trial NCT01491893 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41532826 | Targeting Tumor-Draining Lymph Nodes to Improve the Therapeutic Potential of Oncolytic Viruses. | Cancer immunology research | 2026 | name in abstract: PVSRIPO |
| PMID 41705010 | A Decade of Oncolytic Virotherapy in Pediatric Cancers: A Systematic Review of Safety, Immune Awakening, and Emerging Efficacy. | Cureus | 2026 | name in abstract: PVSRIPO |
| PMID 41741902 | Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors. | Journal of neuro-oncology | 2026 | name in abstract: PVSRIPO |
| PMID 41993267 | Viral Microglia Reprogramming Clears Oligomeric Neurotoxic Debris. | bioRxiv : the preprint server for biology | 2026 | name in abstract: PVSRIPO |
| PMID 42994380 | Overcoming glioma heterogeneity: Strategies to improve the specificity of oncolytic viruses. | Pathology, research and practice | 2026 | name in abstract: PVSRIPO |
| PMID 40313264 | Lymphotropic Virotherapy Engages DC and High Endothelial Venule Inflammation to Mediate Cancer In Situ Vaccination. | medRxiv : the preprint server for health sciences | 2025 | name in abstract: PVSRIPO |
| PMID 40957170 | Oncolytic virus therapy for glioma: current clinical trials and overcoming key obstacles. | International immunopharmacology | 2025 | name in abstract: PVSRIPO |
| PMID 41108331 | The effect of oncolytic virotherapy on pediatric brain tumor- a systematic review. | Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery | 2025 | name in abstract: lerapolturev |
| PMID 41228258 | The Emerging Role of Oncolytic Virotherapy in Glioblastoma Management. | Cancers | 2025 | name in abstract: PVSRIPO |
| PMID 41372729 | Emerging therapies for glioblastoma. | Journal of neuro-oncology | 2025 | name in abstract: PVSRIPO |
| PMID 38183802 | Elucidating cellular response to treatment with viral immunotherapies in pediatric high-grade glioma and medulloblastoma. | Translational oncology | 2024 | name in abstract: PVSRIPO |
| PMID 38689623 | Focus on current and emerging treatment options for glioma: A comprehensive review. | World journal of clinical oncology | 2024 | name in abstract: lerapolturev |
| PMID 38806994 | A viral attack on brain tumors: the potential of oncolytic virus therapy. | Journal of neurovirology | 2024 | name in abstract: PVSRIPO |
| PMID 36301489 | CD155 is a putative therapeutic target in medulloblastoma. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2023 | name in abstract: PVSRIPO |
| PMID 36494005 | Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy. | Annals of oncology : official journal of the European Society for Medical Oncology | 2023 | name in abstract: PVSRIPO |
| PMID 36510843 | Gene Therapy for High Grade Glioma: The Clinical Experience. | Expert opinion on biological therapy | 2023 | name in abstract: PVSRIPO |
| PMID 36864784 | Polio virotherapy targets the malignant glioma myeloid infiltrate with diffuse microglia activation engulfing the CNS. | Neuro-oncology | 2023 | name in abstract: PVSRIPO |
| PMID 37749907 | Oncolytic virotherapies for pediatric tumors. | Expert opinion on biological therapy | 2023 | name in abstract: PVSRIPO |
| PMID 37962360 | Early enterovirus translation deficits extend viral RNA replication and elicit sustained MDA5-directed innate signaling. | mBio | 2023 | name in abstract: PVSRIPO |
| PMID 34004331 | Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme. | Seminars in cancer biology | 2022 | name in abstract: PVSRIPO |
| PMID 35487285 | Clinical advances in oncolytic virotherapy for pediatric brain tumors. | Pharmacology & therapeutics | 2022 | name in abstract: PVSRIPO |
| PMID 35652592 | PKR Binds Enterovirus IRESs, Displaces Host Translation Factors, and Impairs Viral Translation to Enable Innate Antiviral Signaling. | mBio | 2022 | name in abstract: PVSRIPO |
| PMID 33771666 | Oncolytic virus in gliomas: a review of human clinical investigations. | Annals of oncology : official journal of the European Society for Medical Oncology | 2021 | name in abstract: PVSRIPO |
| PMID 34277838 | Current status of intralesional agents in treatment of malignant melanoma. | Annals of translational medicine | 2021 | name in abstract: PVSRIPO |
| PMID 31988324 | Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. | Nature communications | 2020 | name in abstract: PVSRIPO |
| PMID 31428153 | Convection-Enhanced Delivery in Malignant Gliomas: A Review of Toxicity and Efficacy. | Journal of oncology | 2019 | name in abstract: PVSRIPO |
| PMID 29414253 | Recombinant Poliovirus for Cancer Immunotherapy. | Annual review of medicine | 2018 | name in abstract: PVSRIPO |
| PMID 29878245 | Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma. | Journal of neuropathology and experimental neurology | 2018 | name in abstract: PVSRIPO |
| PMID 29997212 | Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells. | Journal of virology | 2018 | name in title: PVSRIPO |
| PMID 30563098 | Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy? | Cancers | 2018 | name in abstract: PVSRIPO |
| PMID 28829151 | Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. | Archives of pathology & laboratory medicine | 2017 | name in abstract: PVSRIPO |
| PMID 28931654 | Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. | Science translational medicine | 2017 | name in abstract: PVSRIPO |
| PMID 27806313 | Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. | Oncotarget | 2016 | name in title: PVSRIPO |
| PMID 28203321 | The Practical Consideration of Poliovirus as an Oncolytic Virotherapy. | American journal of virology | 2016 | name in abstract: PVSRIPO |
| PMID 26083317 | Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus. | Current opinion in virology | 2015 | name in abstract: PVSRIPO |
| PMID 24939611 | Oncolytic polio virotherapy of cancer. | Cancer | 2014 | name in abstract: PVSRIPO |
| PMID 25187540 | Mitogen-activated protein kinase-interacting kinase regulates mTOR/AKT signaling and controls the serine/arginine-rich protein kinase-responsive type 1 internal ribosome entry site-mediated translation and viral oncolysis. | Journal of virology | 2014 | name in abstract: PVSRIPO |
| PMID 25187541 | Induction of viral, 7-methyl-guanosine cap-independent translation and oncolysis by mitogen-activated protein kinase-interacting kinase-mediated effects on the serine/arginine-rich protein kinase. | Journal of virology | 2014 | name in abstract: PVSRIPO |
| PMID 22171271 | Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus:rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis. | Journal of virology | 2012 | name in abstract: PVSRIPO |
| PMID 21984883 | Oncolytic poliovirus against malignant glioma. | Future virology | 2011 | name in abstract: PVSRIPO |
| PMID 20299272 | Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme. | Cytokine & growth factor reviews | 2010 | name in abstract: PVSRIPO |
| PMID 20648000 | MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirus. | Molecular therapy : the journal of the American Society of Gene Therapy | 2010 | name in abstract: PVSRIPO |
| PMID 18951922 | Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay. | Journal of virological methods | 2009 | name in abstract: PVSRIPO |
| PMID 18098139 | Growth phenotypes and biosafety profiles in poliovirus-receptor transgenic mice of recombinant oncolytic polio/human rhinoviruses. | Journal of medical virology | 2008 | name in abstract: PVSRIPO |
| PMID 16489093 | Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2006 | name in abstract: PVSRIPO |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R01CA281320 | Resolving Spatiotemporal Dynamics of Recombinant Poliovirus Immunotherapy | DUKE UNIVERSITY | GROMEIER, MATTHIAS | 2023–2026 | name in abstract: PVSRIPO |
| R01NS108773 | Innate Antiviral Signals for Cancer Immunotherapy | DUKE UNIVERSITY | GROMEIER, MATTHIAS | 2018–2026 | name in abstract: PVSRIPO |
| R37CA315608 | Innate immune memory for glioma immunotherapy | DUKE UNIVERSITY | BROWN, MICHAEL CLAVON | 2026–2026 | name in abstract: PVSRIPO |
| K08CA237726 | PVSRIPO in melanoma | DUKE UNIVERSITY | BEASLEY, GEORGIA | 2020–2024 | name in title: PVSRIPO |
| P01CA225622 | Biostatistics and Bioinformatics Core | DUKE UNIVERSITY | HERNDON, JAMES E | 2018–2022 | name in title: PVSRIPO |
| F32CA224593 | Cancer Immunotherapy Through Intratumoral Activation of Recall Responses | DUKE UNIVERSITY | BROWN, MICHAEL CLAVON | 2018–2020 | name in abstract: PVSRIPO |
| R21NS112899 | Is Low Tumor Mutational Burden Predictive of Response to Oncolytic Polio Virus Therapy in Recurrent Glioblastoma? | DUKE UNIVERSITY | ASHLEY, DAVID M. | 2019–2019 | name in abstract: PVSRIPO |
| P50CA190991 | Oncolytic Immunotherapy of Malignant Glioma | DUKE UNIVERSITY | GROMEIER, MATTHIAS | 2014–2018 | name in abstract: PVSRIPO |
Notes
Live attenuated Sabin type 1 poliovirus whose internal ribosome entry site is replaced by that of human rhinovirus type 2, removing neurovirulence. Given intratumorally, into glioma by convection-enhanced delivery.
How to cite
lerapolturev (AXP000124.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000124.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.